Skip to Main Content


Skip Nav Destination

Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors.

Mol Cancer Ther (2013) 12 (11_Supplement): B281.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Christian Dittrich
  • Michael A. Fridrik
  • Robert Koenigsberg
  • Chooi Lee
  • Rainer-Georg Goeldner
  • James Hilbert
  • Richard Greil
Investigational New Drugs (2015) 33 (2): 409.
Close Modal

or Create an Account

Close Modal
Close Modal